ROTHSTEIN	N STUART									
Form 4										
January 03, 2	2019									
FORM	4								OMB AF	PPROVAL
	• • UNITE	D STATES					GE C	OMMISSION	OMB	3235-0287
Check thi	is box		Was	shington,	D.C. 205 4	1 9			Number:	
if no long	ter.		E CHAN	CECINI	DENIEFIC	TAT	OWN		Expires:	January 31, 2005
subject to)		г UПАN	SECUR		IAL	UWF	NERSHIP OF	Estimated a	
Section 1 Form 4 or				SECUR	11165				burden hou	
Form 5		ursuant to	Section 1	6(a) of the	- Securitie	s Fra	hange	e Act of 1934,	response	0.5
obligation	ns Section 1						-	1935 or Section	n	
may cont See Instru	inue.			•	Company	•				
1(b).	iction	()			· · · · ·					
(Print or Type F	Responses)									
1 37 1 4		D *						5 5 1 4 1 6	D D	
ROTHSTEI	ddress of Reporti	ng Person _		Name and	Ticker or Ti	rading		5. Relationship of Issuer	Reporting Pers	son(s) to
ROMBILI			Symbol	Commono	ial Daal E	atata				
			-	, Inc. [AR	ial Real E	state		(Chec	k all applicable)
		(M (111))			-			V D'	100	0
(Last)	(First)	(Middle)		Earliest Tr	ansaction			X Director X Officer (give		Owner er (specify
C/O APOLI	LO GLOBAL		(Month/D 12/31/2	-				below)	below)	· · ·
	AENT, LLC, 9	WEST	12/31/2	010				Pres	sident & CEO	
	EET, 43RD FL									
	(Street)		4 If Ame	ndment, Da	te Original			6. Individual or Jo	int/Group Filin	o(Check
				nth/Day/Year)	-			Applicable Line)	ind Group I him	g(enter
				· · · · · · · · · · · · · · · · · · ·	, 			_X_ Form filed by C		
NEW YORI	K, NY 10019							Form filed by M Person	Iore than One Re	porting
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative Se	curiti	es Acqu	uired, Disposed of	, or Beneficial	ly Owned
1.Title of	2. Transaction D	Date 2A. Deer	med	3.	4. Securitie	s Acq	uired	5. Amount of	6. Ownership	7. Nature of
Security	(Month/Day/Yea	ar) Executio	on Date, if		on(A) or Disp				Form: Direct	
(Instr. 3)		any (Month/I	Day/Year)	Code (Instr. 8)	(Instr. 3, 4	and 5)		Beneficially Owned	(D) or Indirect (I)	Beneficial Ownership
		(INIOIIUI)	Day/Teal)	(11150. 0)				Following	(Instr. 4)	(Instr. 4)
						(A)		Reported		. ,
						(A) or		Transaction(s)		
				Code V	Amount	(D)	Price	(Instr. 3 and 4)		
Common Stock	12/31/2018			А	115,000	А	\$ 0 (1)	386,938 <u>(1)</u>	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Securi (Instr.	nt of lying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Othe	
ROTHSTEIN STUART C/O APOLLO GLOBAL MANAGEMENT, LLC 9 WEST 57TH STREET, 43RD FLOOR NEW YORK, NY 10019	Х		President & CEO		
Signatures					
/s/ Jessica L. Lomm, as Attorney-in-Fact 01/03	3/2019				

**Signature of Reporting Person

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Date

As of the transaction date, reported amount includes 340,001 restricted stock units ("RSUs") granted under the Apollo Commercial Real Estate Finance, Inc. 2009 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the issuer's common (1) stock for each vested RSU. The RSUs vest in installments in accordance with the terms of the applicable RSU Award Agreement by and

between the reporting person and the issuer, provided the reporting person remains in service through the applicable vesting dates.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. 00%;" class="DSPFListTable" id="zeee5f52c3a574e0dad2a149f7cd9f252">

interest and yield rates in the market generally;

"a variety of economic, financial, political, regulatory or judicial events;

the occurrence of certain events with respect to the Underlying that may or may not require an adjustment to the terms of the Notes: and

"our creditworthiness, including actual or anticipated downgrades in our credit ratings.

Some or all of these factors will influence the terms of the Notes at issuance as well as the price you will receive if you choose to sell the Notes prior to maturity. The impact of any of the factors set forth above may enhance or offset some or all of any change resulting from another factor or factors. You may have to sell the Notes at a substantial discount from the principal amount if, for example, the price of the Underlying is at, below or not sufficiently above, its Downside Threshold.

The Anti-Dilution Protection for the Underlying Is Limited — The calculation agent will make adjustments to the Initial Price, Downside Threshold and Coupon Barrier for certain events affecting the shares of the Underlying. "However, the calculation agent will not be required to make an adjustment in response to all events that could affect the Underlying. If an event occurs that does not require the calculation agent to make an adjustment, the value of the

Notes and the payments on the Notes may be materially and adversely affected.

9

Hypothetical Examples

Hypothetical terms only. Actual terms may vary. See the cover page for actual offering terms. The following examples are hypothetical and provided for illustrative purposes only. They do not purport to be representative of every possible scenario concerning increases or decreases in the price of the Underlying relative to its Initial Price. We cannot predict the Final Price of the Underlying. You should not take these examples as an indication or assurance of the expected performance of the Underlying. The numbers appearing in the examples and tables below have been rounded for ease of analysis. The following examples and tables illustrate the Payment at Maturity or upon an automatic call per Note on a hypothetical offering of the Notes, based on the following hypothetical assumptions (actual terms for the Notes will be set on the Trade Date):

ngponionour assumptions (aota	ar terms for the roces will be set on the ridde Dute).		
Principal Amount:	\$10.00		
Term:	Approximately 1 year		
Hypothetical Initial Price*:	\$100.00		
Hypothetical Contingent	9.50% per annum (or 2.375% per quarter), which is the low end of the Contingent		
Coupon Rate:	Coupon Rate set forth above.		
Hypothetical Contingent	\$0.2375 per quarter		
Coupon**:	\$0.2575 per quarter		
Coupon Observation Dates:	Quarterly		
Call Observation Dates:	Quarterly		
Hypothetical Downside	\$70.00 (which is 70% of the Initial Price)		
Threshold*:	\$70.00 (which is 70% of the initial Price)		
Hypothetical Coupon Barrier*:	\$70.00 (which is 70% of the Initial Price)		

* May not be the actual Initial Price, Contingent Coupon Rate, Coupon Barrier or Downside Threshold applicable to the Notes. The actual Initial Price, Contingent Coupon Rate, Coupon Barrier and Downside Threshold will be determined on the Trade Date.

** Contingent Coupon payments, if payable, will be paid in arrears in equal quarterly installments during the term of the Notes unless earlier called.

Scenario #1: Notes Are Called on the First Coupon Observation Date.

Date	Closing Price	Payment (per Note)
First Coupon Observation	\$105.00 (at or above Coupon Barrier and Initial	\$10.2375 (Call Settlement
Date	Price)	Amount)

Total Payment:

\$10.2375 (2.375% return)

Since the Notes are called on the first Coupon Observation Date, we will pay you on the Call Settlement Date a total of \$10.2375 per Note, reflecting your principal amount plus the applicable Contingent Coupon, for a 2.375% total return on the Notes. No further amount will be owed to you under the Notes.

Scenario #2: Notes Are Called on the Third Coupon Observation Date.					
Date	Closing Price	Payment (per Note)			
First Coupon Observation	\$75.00 (at or above Coupon Barrier; below Initial \$0.2375 (Contingent Coupon - no				
Date	Price)	called)			
Second Coupon Observation	\$73.00 (at or above Coupon Barrier; below Initia	1 \$0.2375 (Contingent Coupon – not			
Date	Price)	called)			
Third Coupon Observation Date	\$105.00 (at or above Initial Price)	\$10.2375 (Call Settlement Amount)			

Total Payment:

\$10.7125 (7.125% return)

Since the Notes are called on the third Coupon Observation Date, we will pay you on the Call Settlement Date a total of \$10.2375 per Note, reflecting your principal amount plus the applicable Contingent Coupon. When added to the Contingent Coupon payments of \$0.475 received in respect of prior Coupon Observation Dates, we will have paid you

a total of \$10.7125 per Note, for a 7.125% total return on the Notes. No further amount will be owed to you under the Notes.

Scenario #3: Notes Are N	NOT Called and the Final Price of the Underlying Is at o	r Above the Downside Threshold.	
Date	Closing Price	Payment (per Note)	
First Coupon Observation	n \$95.00 (at or above Coupon Barrier; below Initial	\$0.2375 (Contingent Coupon – not	
Date	Price)	called)	
Second Coupon	\$60.00 (below Coupon Barrier)	\$0.00 (Contingent Coupon not	
Observation Date	\$00.00 (below Coupoil Barrier)	payable – not called)	
Third Coupon	\$65.00 (below Coupon Barrier; below Initial Price)	\$0.00 (Contingent Coupon not	
Observation Date	\$65.00 (below Coupon Barrier, below mittai Tree)	payable – not called)	
Final Valuation Date	\$72.00 (at or above Downside Threshold and Coupon	\$10.2375 (Payment at Maturity)	
Thial Valuation Date	Barrier; below Initial Price)	\$10.2375 (I ayment at Waturity)	
	Total Payment:	\$10.475 (4.75% return)	

At maturity, we will pay you a total of \$10.2375 per Note, reflecting your principal amount plus the applicable Contingent Coupon. When added to the Contingent Coupon payments of \$0.2375 received in respect of prior Coupon Observation Dates, we will have paid you a total of \$10.475 per Note, for a 4.75% total return on the Notes.

10

Scenario #4: Notes Are NOT Called and the Final Price of the Underlying Is Below the Downside Threshold					
Date	Closing Price	Payment (per Note)			
First Coupon Observation	\$95.00 (at or above Coupon Barrier; below	\$0.2375 (Contingent Coupon – not called)			
Date Second Coupon	Initial Price) \$85.00 (at or above Coupon Barrier; below				
Observation Date Initial Price)		\$0.2375 (Contingent Coupon – not called)			
Third Coupon Observation	\$50.00 (below Coupon Barrier; below Initia	w Coupon Barrier; below Initial\$0.00 (Contingent Coupon not payable –			
Date	Price)	Notes not called)			
		$10.00 + [10.00 \times underlying return] =$			
Final Valuation Date	\$25.00 (below Downside Threshold and	\$10.00 + [\$10.00 × -75%] = \$10.00 - \$7.50 =			
Thial Valuation Date	Coupon Barrier)				
		\$2.50 (Payment at Maturity)			
	Total Payment:	\$2.975 (-70.25% return)			

Since the Notes are not called and the Final Price of the Underlying is below the Downside Threshold, we will pay you at maturity \$2.50 per Note. When added to the Contingent Coupon payments of \$0.475 received in respect of prior Coupon Observation Dates, we will have paid you \$2.975 per Note, for a loss on the Notes of 70.25%.

The Notes differ from ordinary debt securities in that, among other features, we are not necessarily obligated to repay the full amount of your initial investment. If the Notes are not called on any Call Observation Date, you may lose some or all of your initial investment. Specifically, if the Notes are not called and the Final Price is less than the Downside Threshold, you will lose 1% (or a fraction thereof) of your principal amount for each 1% (or a fraction thereof) that the underlying return is less than zero.

Any payment on the Notes, including payments in respect of an automatic call, Contingent Coupon or any repayment of principal provided at maturity, is dependent on our ability to satisfy our obligations when they come due. If we are unable to meet our obligations, you may not receive any amounts due to you under the Notes.

11

What Are the Tax Consequences of the Notes?

U.S. Federal Income Tax Consequences

The following, together with the discussion of U.S. federal income tax in the accompanying product prospectus supplement, prospectus supplement, and prospectus, is a general description of the material U.S. federal income tax consequences relating to an investment in the Notes. The following summary is not complete and is qualified in its entirety by the discussion under the section entitled "Supplemental Discussion of U.S. Federal Income Tax Consequences" in the accompanying product prospectus supplement no. UBS-TACYN-1, the section entitled "Certain Income Tax Consequences" in the accompanying prospectus supplement, and the section entitled "Tax Consequences" in the accompanying prospectus, which you should carefully review prior to investing in the Notes. In the opinion of our counsel, Morrison & Foerster LLP, it would generally be reasonable to treat the Notes as a callable pre-paid cash-settled contingent income-bearing derivative contract linked to the applicable Underlying for U.S. federal income tax purposes, and the terms of the Notes require a holder and us (in the absence of a change in law or an administrative or judicial ruling to the contrary) to treat the Notes for all tax purposes in accordance with such characterization. Although the U.S. federal income tax treatment of the Contingent Coupons is uncertain, we intend to take the position, and the following discussion assumes, that such Contingent Coupons (including any coupon paid on or with respect to the call or maturity date) constitute taxable ordinary income to a U.S. holder at the time received or accrued in accordance with the holder's regular method of accounting. If the Notes are treated as described above, subject to the potential application of the "constructive ownership" rules under Section 1260 of the Internal Revenue Code, a U.S. holder should generally recognize capital gain or loss upon the call, sale or maturity of the Notes in an amount equal to the difference between the amount a holder receives at such time (other than amounts properly attributable to any Contingent Coupon, which would be taxed, as described above, as ordinary income) and the holder's tax basis in the Notes. Capital gain recognized by an individual U.S. holder is generally taxed at preferential rates where the property is held for more than one year and is generally taxed at ordinary income rates where the property is held for one year or less. The deductibility of capital losses is subject to limitations. Alternative tax treatments are also possible and the Internal Revenue Service (the "IRS") might assert that a treatment other than that described above is more appropriate. In addition, the IRS has released a notice that may affect the taxation of holders of the Notes. According to the notice, the IRS and the Treasury Department are actively

taxation of holders of the Notes. According to the notice, the IRS and the Treasury Department are actively considering whether the holder of an instrument such as the Notes should be required to accrue ordinary income on a current basis. It is not possible to determine what guidance they will ultimately issue, if any. It is possible, however, that under such guidance, holders of the Notes will ultimately be required to accrue income currently and this could be applied on a retroactive basis. The IRS and the Treasury Department are also considering other relevant issues, including whether additional gain or loss from such instruments should be treated as ordinary or capital and whether the special "constructive ownership rules" of Section 1260 of the Internal Revenue Code might be applied to such instruments. Holders are urged to consult their tax advisors concerning the significance, and the potential impact, of the above considerations.

Individual holders that own "specified foreign financial assets" may be required to include certain information with respect to such assets with their U.S. federal income tax return. You are urged to consult your own tax advisor regarding such requirements with respect to the Notes.

Under Section 871(m) of the Internal Revenue Code, a "dividend equivalent" payment is treated as a dividend from sources within the United States. Such payments generally would be subject to a 30% U.S. withholding tax if paid to a non-U.S. holder. Under U.S. Treasury Department regulations, payments (including deemed payments) with respect to equity-linked instruments ("ELIs") that are "specified ELIs" may be treated as dividend equivalents if such specified ELIs reference an interest in an "underlying security," which is generally any interest in an entity taxable as a corporation for U.S. federal income tax purposes if a payment with respect to such interest could give rise to a U.S. source dividend. However, the IRS has issued guidance that states that the U.S. Treasury Department and the IRS intend to amend the effective dates of the U.S. Treasury Department regulations to provide that withholding on dividend equivalent payments will not apply to specified ELIs that are not delta-one instruments and that are issued before January 1, 2021. Based on our determination that the Notes are not delta-one instruments, non-U.S. holders should not be subject to withholding on dividend equivalent payments, if any, under the Notes. However, it is possible that the Notes could be treated as deemed reissued for U.S. federal income tax purposes upon the occurrence of certain events affecting the

applicable Underlying or the Notes, and following such occurrence the Notes could be treated as subject to withholding on dividend equivalent payments. Non-U.S. holders that enter, or have entered, into other transactions in respect of the applicable Underlying or the Notes should consult their tax advisors as to the application of the dividend equivalent withholding tax in the context of the Notes and their other transactions. If any payments are treated as dividend equivalents subject to withholding, we (or the applicable withholding agent) would be entitled to withhold taxes without being required to pay any additional amounts with respect to amounts so withheld.

The accompanying product prospectus supplement notes that FATCA withholding on payments of gross proceeds from a sale or redemption of Notes will only apply to payments made after December 31, 2018. That discussion is modified to reflect regulations proposed by the U.S. Treasury Department in December 2018 indicating an intent to eliminate the requirement under FATCA of withholding on gross proceeds of the disposition of financial instruments. The U.S. Treasury Department has indicated that taxpayers may rely on these proposed regulations pending their finalization. Prospective investors are urged to consult with their own tax advisors regarding the possible implications of FATCA on their investment in the Notes.

The Notes are not intended for purchase by any investor that is not a United States person, as that term is defined for U.S. federal income tax purposes, and the underwriters will not make offers of the Notes to any such investor. Canadian Federal Income Tax Consequences

For a discussion of the material Canadian federal income tax consequences relating to an investment in the Notes, please see the section entitled "Tax Consequences—Canadian Taxation" in the accompanying prospectus, which you should carefully review prior to investing in the Notes.

Information About the Underlying

Included on the following pages is a brief description of the Underlying. This information has been obtained from publicly available sources. Set forth below is a table that provides the quarterly high, low and period-end closing prices for the Underlying. We obtained the closing price information set forth below from the Bloomberg Professional[®] service ("Bloomberg") without independent verification. You should not take the historical prices of the Underlying as an indication of future performance.

The Underlying is registered under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Companies with securities registered under the Exchange Act are required to periodically file financial and other information specified by the SEC. Information filed by the Underlying with the SEC can be reviewed electronically through a website maintained by the SEC. The address of the SEC's website is http://www.sec.gov. Information filed with the SEC by the issuer of the Underlying under the Exchange Act can be located by reference to its SEC Central Index Key ("CIK") number provided below. Information from outside sources is not incorporated by reference in, and should not be considered part of, this free writing prospectus or any accompanying prospectus or prospectus supplement. We have not independently verified the accuracy or completeness of the information contained in outside sources.

CVS Health Corporation

According to publicly available information, CVS Health Corporation is a pharmacy health care provider. Its offerings include pharmacy benefit management services; mail order, retail and specialty pharmacy; disease management programs; and retail clinics.

Information filed by the company with the SEC under the Exchange Act can be located by reference to its SEC CIK number: 0000064803. The company's common stock is listed on the New York Stock Exchange under the ticker symbol "CVS."

Historical Information

The graph below illustrates the performance of the Underlying from March 20, 2009 to March 20, 2019, assuming an Initial Price of \$56.16, which was its closing price on March 20, 2019. The solid line represents a hypothetical Coupon Barrier and Downside Threshold of \$39.31, which is equal to 70% of the closing price on March 20, 2019 (rounded to two decimal places). The actual Coupon Barrier and Downside Threshold will be based on the closing price of CVS on the Trade Date.

n Hypothetical Coupon Barrier / Downside Threshold = 70%

HISTORIC PERFORMANCE IS NOT AN INDICATION OF FUTURE PERFORMANCE.

Source: Bloomberg L.P. We have not independently verified the accuracy or completeness of the information obtained from Bloomberg Financial Markets.

Supplemental Plan of Distribution (Conflicts of Interest)

We have agreed to indemnify UBS and RBCCM against liabilities under the Securities Act of 1933, as amended, or to contribute payments that UBS and RBCCM may be required to make relating to these liabilities as described in the prospectus supplement and the prospectus. We will agree that UBS Financial Services Inc. may sell all or a part of the Notes that it will purchase from us to investors at the price to public or to its affiliates at the price indicated on the cover of the pricing supplement, the document that will be filed under Rule 424(b)(2) containing the final pricing terms of the Notes.

We expect to deliver the Notes on a date that is greater than two business days following the trade date. Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in two business days, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the Notes more than two business days prior to the original issue date will be required to specify alternative settlement arrangements to prevent a failed settlement.

Subject to regulatory constraints and market conditions, RBCCM intends to offer to purchase the Notes in the secondary market, but it is not required to do so.

We or our affiliates may enter into swap agreements or related hedge transactions with one of our other affiliates or unaffiliated counterparties in connection with the sale of the Notes and RBCCM and/or an affiliate may earn additional income as a result of payments pursuant to the swap or related hedge transactions. See "Use of Proceeds and Hedging" in the accompanying product prospectus supplement no. UBS-TACYN-1.

The value of the Notes shown on your account statement may be based on RBCCM's estimate of the value of the Notes if RBCCM or another of our affiliates were to make a market in the Notes (which it is not obligated to do). That estimate will be based upon the price that RBCCM may pay for the Notes in light of then prevailing market conditions, our creditworthiness and transaction costs. If so specified in the pricing supplement related to the Notes, for a period of approximately 6 months after the issue date of the Notes, the value of the Notes that may be shown on your account statement may be higher than RBCCM's estimated value of the Notes at that time. This is because the estimated value of the Notes will not include the underwriting discount and our hedging costs and profits; however, the value of the Notes shown on your account statement during that period may be a higher amount, potentially reflecting the addition of the underwriting discount and our estimated costs and profits from hedging the Notes. Any such excess is expected to decrease over time until the end of this period. After this period, if RBCCM repurchases your Notes, it expects to do so at prices that reflect their estimated value. This period may be reduced at RBCCM's discretion based on a variety of factors, including but not limited to, the amount of the Notes that we repurchase and our negotiated arrangements from time to time with UBS.

For additional information as to the relationship between us and RBCCM, please see the section "Plan of Distribution—Conflicts of Interest" in the prospectus dated September 7, 2018.

Structuring the Notes

The Notes are our debt securities, the return on which is linked to the performance of the Underlying. As is the case for all of our debt securities, including our structured notes, the economic terms of the Notes reflect our actual or perceived creditworthiness at the time of pricing. In addition, because structured notes result in increased operational, funding and liability management costs to us, we typically borrow the funds under these Notes at a rate that is more favorable to us than the rate that we might pay for a conventional fixed or floating rate debt security of comparable maturity. Using this relatively lower implied borrowing rate rather than the secondary market rate is a factor that is likely to result in a higher initial estimated value of the Notes at the time their terms are set than if the secondary market rate was used. Unlike the estimated value included in the final pricing supplement relating to the Notes, any value of the Notes determined for purposes of a secondary market transaction may be based on a different borrowing rate, which may result in a lower value for the Notes, we may choose to enter into certain hedging arrangements (which may include call options, put options or other derivatives) on the issue date with RBCCM or one of our other subsidiaries. The terms of these hedging arrangements take into account a number of factors, including our creditworthiness, interest rate movements, the volatility of the Underlying, and the tenor of the Notes. The economic terms of the Notes and their initial estimated value depend in part on the terms of these hedging arrangements.

The lower implied borrowing rate is a factor that reduces the economic terms of the Notes to you. The initial offering price of the Notes also reflects the underwriting commission and our estimated hedging costs. These factors result in the initial estimated value for the Notes on the Trade Date being less than their public offering price. See "Key Risks—The Initial Estimated Value of the Notes Will Be Less than the Price to the Public" above.

Terms Incorporated in Master Note

The terms appearing above under the caption "Indicative Terms of the Notes" and the provisions in the accompanying product prospectus supplement no. UBS-TACYN-1 dated October 3, 2018 under the caption "General Terms of the Securities" are incorporated into the master note issued to DTC, the registered holder of the Notes.